Enhanced thrombolytic and antithrombotic potency of a fibrin-targeted plasminogen activator in baboons

Circulation

Volumn 94, Issue 6, 1996, Pages 1412-1422

  Runge, Marschall S ^a   Harker, Laurence A ^c   Bode, Christoph ^g   Ruef, Johannes ^g   Kelly, Andrew B ^d   Marzec, Ulla M ^c   Allen, Elaine ^b   Caban, Rafael ⁱ   Shaw, Shyh Yu ^h   Haber, Edgar ^f   Hanson, Stephen R ^c,e  

^a University of Texas Medical Branch School of Medicine   (United States)

^b ARIAD PHARMACEUTICALS INC   (United States)

^c Division of Hematology/Oncology   (United States)

^d EMORY UNIVERSITY   (United States)

^e EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g Medizinische Klinik III   (Germany)

^h BRISTOL MYERS SQUIBB   (United States)

ⁱ NONE

Author keywords

arteriosclerosis; plasminogen activators; thrombolysis; thrombosis

Indexed keywords

ALTEPLASE; FIBRIN ANTIBODY; HEPARIN; RECOMBINANT PLASMINOGEN ACTIVATOR; UROKINASE;

ANIMAL MODEL; ANTICOAGULATION; ARTICLE; BABOON; BLEEDING; CORONARY ARTERY THROMBOSIS; DRUG EFFECT; DRUG POTENCY; FIBRINOLYTIC THERAPY; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; PRIORITY JOURNAL;

EID: 9544229716     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.94.6.1412     Document Type: Article

References (39)

1. Aberg A, Bergstrand R, Johansson S, Ulvenstam G, Vedin A, Wedel H. Declining trend in mortality after myocardial infarction. Br Heart J. 1984;51:346-351.
2. AIMS Trial Study Group. Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. Lancet. 1988;1:545-549.
3. GISSI (Gruppo Italiano per lo Studio della Streptochinasi nell'Infarto Miocardico). Effectiveness of intravenous thrombolytic treatment in acute myocardial infarction. Lancet. 1986;1:397. Letter.
4. ISIS Steering Committee. Intravenous streptokinase given within 0-4 hours of onset of myocardial infarction reduced mortality in ISIS-2. Lancet. 1987;1:502. Letter.
5. Chesebro JH, Knatterud G, Braunwald E. Thrombolytic therapy. N Engl J Med. 1988;319:1544-1545.
6. TIMI Study Group. The Thrombolysis in Myocardial Infarction (TIMI) trial: phase I findings. N Engl J Med. 1985;312:932-936.
7. Topol EJ, Califf RM, George BS, Kereiakes DJ, Abbottsmith CW, Candela RJ, Lee KL, Pitt B, Stack RS, O'Neill WW. A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction. N Engl J Med. 1987;317:581-588.
8. Bode C, Meinhardt G, Runge MS, Freitag M, Nordt T, Arens M, Newell JB, Kubler W, Haber E. Platelet-targeted fibrinolysis enhances clot lysis and inhibits platelet aggregation. Circulation. 1991;84:805-813.
9. Browne MJ, Carey JE, Chapman CG, Tyrrell AW, Entwisle C, Lawrence GM, Reavy B, Dodd I, Esmail A, Robinson JH. A tissue-type plasminogen activator mutant with prolonged clearance in vivo: effect of removal of the growth factor domain. J Biol Chem. 1988;263:1599-1602.
10. Jackson CV, Crowe VG, Craft TJ, Sundboom JL, Grinnell BW, Bobbitt JL, Burck PJ, Quay JF, Smith GF. Thrombolytic activity of a novel plasminogen activator, LY210825, compared with recombinant tissue-type plasminogen activator in a canine model of coronary artery thrombosis. Circulation. 1990;82:1062-1063.
11. Holvoet PY, Laroche Y, Lijnen HR, Van Cauwenberge R, Demarsin E, Brouwers E, Matthyssens G, Collen D. Characterization of a chimeric plasminogen activator consisting of a single-chain Fv fragment derived from a fibrin fragment D-dimer-specific antibody and a truncated single-chain urokinase. J Biol Chem. 1991;266:19717-19724.
12. Larsen GR, Henson K, Blue Y. Variants of human tissue-type plasminogen activator: fibrin binding, fibrinolytic, and fibrinogenolytic characterization of genetic variants lacking the fibronectin finger-like and/or the epidermal growth factor domains. J Biol Chem. 1988;263:1023-1029.
13. Lijnen HR, Nelles L, Holmes WE, Collen D. Biochemical and thrombolytic properties of a low molecular weight form (comprising Leu144 through Leu411) of recombinant single-chain urokinase-type plasminogen activator. J Biol Chem. 1988;263:5594-5598.
14. Lijnen HR, Nelles L, Van Hoef B, De Cock F, Collen D. Biochemical and functional characterization of human tissue-type plasminogen activator variants obtained by deletion and/or duplication of structural/ functional domains. J Biol Chem. 1990;265:5677-5683.
15. Madison EL, Goldsmith EJ, Gerard RD, Gething MJ, Sambrook JF. Serpin-resistant mutants of human tissue-type plasminogen activator. Nature. 1989;339:721-724.
16. Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of recombinant human single chain urokinase-type plasminogen activator mutants produced by site-specific mutagenesis of lysine 158. J Biol Chem. 1987;262:5682-5689.
17. Nelles L, Lijnen HR, Collen D, Holmes WE. Characterization of a fusion protein consisting of amino acids 1 to 263 of tissue-type plasminogen activator and amino acids 144 to 411 of urokinase-type plasminogen activator. J Biol Chem. 1987;262:10855-10862.
18. Runge MS, Bode C, Matsueda GR, Haber E. Conjugation to an antifibrin monoclonal antibody enhances the fibrinolytic potency of tissue plasminogen activator in vitro. Biochemistry. 1988;27: 1153-1157.
19. Runge MS, Quertermous T, Zavodny PJ, Love TW, Bode C, Freitag M, Shaw SY, Huang PL, Chou D, Mullins D, Schnee JM, Savard CE, Rothenberg ME, Newell JB, Matsueda GR, Haber E. A recombinant chimeric plasminogen activator with high affinity for fibrin has increased thrombolytic potency in vitro and in vivo. Proc Natl Acad Sci U S A. 1991;88:10337-10341.
20. Schnee JM, Runge MS, Matsueda GR, Hudson NW, Seidman JG, Haber E, Quertermous T. Construction and expression of a recombinant antibody-targeted plasminogen activator. Proc Natl Acad Sci U S A. 1987;84:6904-6908.
21. Heras M, Chesebro JH, Penny WJ, Bailey KR, Badimon L, Fuster V. Effects of thrombin inhibition on the development of acute platelet-thrombus deposition during angioplasty in pigs: heparin versus recombinant hirudin, a specific thrombin inhibitor. Circulation. 1989;79:657-665.
22. Jang I, Gold HK, Leinbach RC, McNary JE, Fallon JT, Collen D. Acceleration of reperfusion by combination of rt-PA and a selective thrombin inhibitor, argatroban. Circulation. 1989;80(suppl II):II-217. Abstract.
23. Parise P, Agnelli G. Thrombus resistance to lysis and reocclusion after thrombolysis: the role of platelets. Blood Coagul Fibrinol. 1991;2:749-758.
24. Rudd MA, George D, Johnstone MT, Moore RT, Collins L, Rabbani LE, Loscalzo J. Effect of thrombin inhibition on the dynamics of thrombolysis and on platelet function during thrombolytic therapy. Circ Res. 1992;70:829-834.
25. Yasuda T, Gold HK, Leinbach RC, Yaoita H, Fallon JT, Guerrero L, Napier MA, Bunting S, Collen D. Kistrin, a polypeptide platelet GPIIb/IIIa receptor antagonist, enhances and sustains coronary arterial thrombolysis with recombinant tissue-type plasminogen activator in a canine preparation. Circulation. 1991;83:1038-1047.
26. 111Indium-labeled platelets in baboons. Blood. 1986;68:386-393.
27. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature. 1970;227:680-685.
28. Yang WP, Goldstein J, Procyk R, Matsueda GR, Shaw SY. Design and evaluation of a thrombin-activable plasminogen activator. Biochemistry. 1994;33:606-612.
29. Harker LA, Hanson SR. Experimental arterial thromboembolism in baboons: mechanisms, quantitation and pharmacologic prevention. J Clin Invest. 1979;64:559-560.
30. Cadroy Y, Harker LA, Hanson SR. Inhibition of platelet-dependent thrombosis by low molecular weight heparin (CY222): comparison with standard heparin. J Lab Clin Med. 1989;114:349-357.
31. Hanson SR, Kotze HF, Savage B, Harker LA. Platelet interactions with Dacron vascular grafts: a model of acute thrombosis in baboons. Arteriosclerosis. 1985;5:595-603.
32. Schneider PA, Hanson SR, Price TM, Harker LA. Confluent durable endothelialization of endarterectomized baboon aorta by early attachment of cultured endothelial cells. J Vasc Surg. 1990;11:365-372.
33. Hanson S, Harker L. Interruption of acute platelet-dependent thrombosis by the synthetic antithrombin D-phenylalanyl-L-prolyl-L-arginyl chloromethyl ketone. Proc Natl Acad Sci U S A. 1988;85:3184-3188.
34. Kelly AB, Marzec UM, Krupski W, Bass A, Cadroy Y, Hanson SR, Harker LA. Hirudin interruption of heparin-resistant arterial thrombus formation in baboons. Blood. 1991;77:1006-1012.
35. Runge MS, Bode C, Matsueda GR, Haber E. Antibody-enhanced thrombolysis: targeting of tissue plasminogen activator in vivo. Proc Natl Acad Sci U S A. 1987;84:7659-7662.
36. Cadroy Y, Maraganore JM, Hanson SR, Harker LA, Selective inhibition by a synthetic hirudin peptide of fibrin-dependent thrombosis in baboons. Proc Natl Acad Sci U S A. 1991;88:1177-1181.
37. Gruber A, Hanson SR, Kelly AB, Yan BS, Bang N, Griffin JH, Harker LA. Inhibition of thrombus formation by activated recombinant protein C in a primate model of arterial thrombosis. Circulation. 1990;82:578-585.
38. Holvoet P, Laroche Y, Stassen JM, Lijnen HR, Van Hoef B, De Cock F, Van Houtven A, Gansemans Y, Matthyssens G, Collen D. Pharmacokinetic and thrombolytic properties of chimeric plasminogen activators consisting of a single-chain Fv fragment of a fibrin-specific antibody fused to single-chain urokinase. Blood. 1993;81:696-703.
39. Gimple LW, Gold HK, Leinbach RC, Coller BS, Werner W, Yasuda T, Johns JA, Ziskind AA, Finkelstein D, Collen D. Correlation between template bleeding times and spontaneous bleeding during treatment of acute myocardial infarction with recombinant tissue-type plasminogen activator. Circulation. 1989; 80:581-588.